Neil Almstead, an insider of Ptc Therapeutics Inc, currently EVP Research Pharma Ops & Tech lately disclosed a trade with the U.S. SEC. As published in the legal form, Neil Almstead made a sale of 703 shares of the New Jersey-based company, priced at $18.0 per share. $12,675 USD was the trade’s value. The SEC document’s date was January 09, 2018. In the last 30 days, he also unloaded 77 shares that are worth $1,361 USD. Neil Almstead presently owns 22,279 shares or 0.05% of Ptc Therapeutics Inc’s market cap.
PROS Holdings, Inc. provides revenue and profit realization software solutions worldwide. The company has market cap of $859.58 million. The Company’s solutions allow clients to experience revenue growth, sustained profitability, and modernized business processes across a range of industries, including manufacturing, distribution, services, and travel. It currently has negative earnings. The firm offers SellingPRO solutions, which include configuration, quoting, and eCommerce capabilities with data science; and PricingPRO solutions that provides pricing recommendations services, as well as controls pricing execution.
Investors sentiment increased to 1.71 in 2017 Q3. Its up 0.79, from 0.92 in 2017Q2. It is positive, as 13 investors sold PTC Therapeutics, Inc. shares while 28 reduced holdings. 25 funds opened positions while 45 raised stakes. 32.89 million shares or 5.85% more from 31.07 million shares in 2017Q2 were reported. Great West Life Assurance Company Can has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT). Canada Pension Plan Board has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Wellington Mngmt Gp Ltd Liability Partnership reported 0.01% stake. Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT). Credit Suisse Ag holds 0% or 57,666 shares. Pennsylvania-based Vanguard Inc has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Brandywine Glob Inv Management Limited Co holds 0% or 1 shares. Secor Cap Advsrs Lp has 0.05% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 23,722 shares. Macquarie Gp Limited invested in 0% or 5,100 shares. 229,338 are held by Qs Invsts Limited Company. The Pennsylvania-based Sei Invs has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). 329,097 are held by Ubs Asset Mgmt Americas. Legal & General Grp Public Limited Company has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Federated Investors Inc Pa, a Pennsylvania-based fund reported 2,551 shares. New York State Common Retirement Fund holds 0% or 52,772 shares in its portfolio.
Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 1 Sell and 7 Hold. Therefore 33% are positive. PTC Therapeutics has $135 highest and $6 lowest target. $33.60’s average target is 62.55% above currents $20.67 stock price. PTC Therapeutics had 34 analyst reports since July 31, 2015 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Hold” rating in Wednesday, August 9 report. Wedbush maintained it with “Outperform” rating and $27 target in Wednesday, February 24 report. J.P. Morgan upgraded the shares of PTCT in report on Thursday, November 16 to “Hold” rating. The stock has “Hold” rating by Cowen & Co on Friday, June 30. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Sector Perform” rating given on Wednesday, February 24 by RBC Capital Markets. The firm has “Sell” rating by J.P. Morgan given on Monday, October 9. On Friday, July 31 the stock rating was maintained by RBC Capital Markets with “Outperform”. RBC Capital Markets maintained the shares of PTCT in report on Friday, November 11 with “Sector Perform” rating. The rating was initiated by Citigroup with “Buy” on Tuesday, August 25. The company was downgraded on Monday, October 9 by JP Morgan.
Since January 3, 2018, it had 0 buys, and 2 insider sales for $8,641 activity. The insider Utter Christine Marie sold 412 shares worth $7,280. Almstead Neil Gregory sold 77 shares worth $1,361.
Analysts await PTC Therapeutics, Inc. (NASDAQ:PTCT) to report earnings on March, 15. They expect $-0.23 EPS, up 70.51% or $0.55 from last year’s $-0.78 per share. After $-0.67 actual EPS reported by PTC Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -65.67% EPS growth.
The stock increased 2.12% or $0.43 during the last trading session, reaching $20.67. About 1.59 million shares traded or 67.68% up from the average. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 104.51% since January 10, 2017 and is uptrending. It has outperformed by 87.81% the S&P500.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company has market cap of $857.59 million. The companyÂ’s lead product is Translarna , for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It currently has negative earnings. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy.
Since January 1, 0001, it had 0 insider purchases, and 4 selling transactions for $3.57 million activity.
Analysts await PROS Holdings, Inc. (NYSE:PRO) to report earnings on February, 6. They expect $-0.30 EPS, up 18.92% or $0.07 from last year’s $-0.37 per share. After $-0.33 actual EPS reported by PROS Holdings, Inc. for the previous quarter, Wall Street now forecasts -9.09% EPS growth.
Sagard Capital Partners Management Corp holds 15.27% of its portfolio in PROS Holdings, Inc. for 1.07 million shares. Whetstone Capital Advisors Llc owns 509,348 shares or 5.6% of their US portfolio. Moreover, Daruma Capital Management Llc has 2.57% invested in the company for 1.71 million shares. The Pennsylvania-based Conestoga Capital Advisors Llc has invested 1.78% in the stock. Df Dent & Co Inc, a Maryland-based fund reported 2.70 million shares.